A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 2000

Conditions

HIV Infections

Interventions

BIOLOGICAL

MN rgp120/HIV-1 and A244 rgp120/HIV-1

BIOLOGICAL

QS-21

BIOLOGICAL

rgp120/HIV-1MN

Trial Locations (4)

Univ. of Rochester AVEG, Rochester

JHU AVEG, Baltimore

Vanderbilt Univ. Hosp. AVEG, Nashville

UW - Seattle AVEG, Seattle

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH